MedPath

CASE WESTERN RESERVE UNIVERSITY

CASE WESTERN RESERVE UNIVERSITY logo
🇺🇸United States
Ownership
Private
Established
1826-01-01
Employees
5K
Market Cap
-
Website
https://case.edu/dental

Clinical Trials

149

Active:8
Completed:101

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:6
Phase 2:5
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (133 trials with phase data)• Click on a phase to view related trials

Not Applicable
114 (85.7%)
Phase 1
6 (4.5%)
Phase 2
5 (3.8%)
Phase 4
4 (3.0%)
Phase 3
3 (2.3%)
Early Phase 1
1 (0.8%)

Developing Resilience and Anxiety Management Through the Arts

Not Applicable
Recruiting
Conditions
Anxiety
Depression
Mood
First Posted Date
2025-06-24
Last Posted Date
2025-06-24
Lead Sponsor
Case Western Reserve University
Target Recruit Count
110
Registration Number
NCT07033052
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

Community-Engaged Sleep Intervention for School-Aged Children With Autism Spectrum Disorder

Not Applicable
Not yet recruiting
Conditions
Behavioral Sleep and Circadian Intervention
Sleep Disturbance
Autism Spectrum Disorder
First Posted Date
2025-06-06
Last Posted Date
2025-06-06
Lead Sponsor
Case Western Reserve University
Target Recruit Count
50
Registration Number
NCT07007819
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)

Not Applicable
Not yet recruiting
Conditions
Schizophrenia
Schizo Affective Disorder
Schizophreniform Disorders
First Posted Date
2025-06-05
Last Posted Date
2025-06-05
Lead Sponsor
Case Western Reserve University
Target Recruit Count
30
Registration Number
NCT07006935
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting

Not Applicable
Not yet recruiting
Conditions
Urinary Tract Infections
First Posted Date
2025-05-16
Last Posted Date
2025-05-16
Lead Sponsor
Case Western Reserve University
Target Recruit Count
47
Registration Number
NCT06976125
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

Nourishing Tomorrow: Role of Medically Tailored Groceries in Addressing Food Insecurity During Pregnancy

Not Applicable
Not yet recruiting
Conditions
Pregnancy Related
Prematurity
Birth Outcome, Adverse
First Posted Date
2025-05-11
Last Posted Date
2025-06-08
Lead Sponsor
Case Western Reserve University
Target Recruit Count
360
Registration Number
NCT06965530
Locations
🇺🇸

MetroHealth Medical Center, Cleveland, Ohio, United States

🇺🇸

University Hospitals Rainbow Ahuja Women and Children's Center, Cleveland, Ohio, United States

🇺🇸

Greater Cleveland Food Bank, Cleveland, Ohio, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 30
  • Next

News

Gabapentin Linked to Increased Dementia Risk in Chronic Pain Patients

A large medical records study found that receiving six or more gabapentin prescriptions for chronic low back pain was associated with 29% increased dementia risk and 85% increased mild cognitive impairment risk within 10 years.

NervGen Appoints Randall Kaye as Chief Medical Advisor Following Positive Spinal Cord Injury Trial Results

NervGen Pharma has appointed Dr. Randall Kaye as Chief Medical Advisor to guide the clinical and regulatory strategy for NVG-291, following positive topline results from the chronic cohort of their Phase 1b/2a spinal cord injury trial.

NSF Awards $500K Grant to Advance Synthetic DNA Nanoparticles for Targeted Gene Therapy

Dr. Divita Mathur at Case Western Reserve University received a prestigious NSF CAREER grant to develop synthetic DNA nanoparticles that can deliver therapeutic genes with precise targeting capabilities.

Trailhead Biosystems Secures $20M to Advance iPSC Technology for Drug Discovery and Regenerative Medicine

Trailhead Biosystems has raised $20 million in funding led by MAK Capital to enhance its portfolio of induced pluripotent stem cell (iPSC) derived cells for research applications.

American Heart Association Awards $1M to Study GLP-1 Medications' Impact on Cardiovascular Risk

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

Semaglutide Shows Promise for Slowing Biological Aging and Improving Cognition in HIV Patients

Semaglutide treatment slowed biological aging by approximately 9% and reduced epigenetic aging mortality risk by three years in HIV patients with lipohypertrophy over 32 weeks.

FDA Clears First Wireless, Catheter-Free Urodynamics System for Bladder Dysfunction Testing

The FDA has granted 510(k) clearance to Bright Uro's Glean™ Urodynamics System, the first wireless, catheter-free device for monitoring bladder dysfunction in patients with lower urinary tract conditions.

Novel Screening Technologies Enter Clinical Trial to Detect Silent Esophageal Precancer

University Hospitals and Case Western Reserve University launch an $8 million NIH-funded clinical trial to evaluate EsoCheck and EsoGuard technologies for detecting Barrett's Esophagus in non-GERD patients.

MedPacto Advances Vactosertib to Phase 2 Trial for Pediatric Osteosarcoma Treatment in US

MedPacto partners with leading US institutions, including Stanford University and Case Western Reserve University, to conduct Phase 2 trial of vactosertib for pediatric osteosarcoma treatment.

Semaglutide Associated with Reduced Alzheimer's Risk in Type 2 Diabetes Patients

A new study indicates that semaglutide, the active ingredient in Ozempic, may significantly reduce the risk of Alzheimer's disease in individuals with type 2 diabetes.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.